Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum

Abstract Background The aim of the present work was to assess i) ex vivo activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities compared to other partner drugs, namely monodesethy...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Pascual Aurélie, Parola Philippe, Benoit-Vical Françoise, Simon Fabrice, Malvy Denis, Picot Stéphane, Delaunay Pascal, Basset Didier, Maubon Danièle, Faugère Bernard, Ménard Guillaume, Bourgeois Nathalie, Oeuvray Claude, Didillon Eric, Rogier Christophe, Pradines Bruno
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2012
Subjects:
Rho
Online Access:https://doi.org/10.1186/1475-2875-11-45
https://doaj.org/article/9ec13234059144b18c4e63182e29403b
id ftdoajarticles:oai:doaj.org/article:9ec13234059144b18c4e63182e29403b
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:9ec13234059144b18c4e63182e29403b 2023-05-15T15:15:52+02:00 Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum Pascual Aurélie Parola Philippe Benoit-Vical Françoise Simon Fabrice Malvy Denis Picot Stéphane Delaunay Pascal Basset Didier Maubon Danièle Faugère Bernard Ménard Guillaume Bourgeois Nathalie Oeuvray Claude Didillon Eric Rogier Christophe Pradines Bruno 2012-02-01T00:00:00Z https://doi.org/10.1186/1475-2875-11-45 https://doaj.org/article/9ec13234059144b18c4e63182e29403b EN eng BMC http://www.malariajournal.com/content/11/1/45 https://doaj.org/toc/1475-2875 doi:10.1186/1475-2875-11-45 1475-2875 https://doaj.org/article/9ec13234059144b18c4e63182e29403b Malaria Journal, Vol 11, Iss 1, p 45 (2012) Malaria Plasmodium falciparum Anti-malarial In vitro Resistance Pyronaridine Piperaquine Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2012 ftdoajarticles https://doi.org/10.1186/1475-2875-11-45 2022-12-31T08:52:26Z Abstract Background The aim of the present work was to assess i) ex vivo activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities compared to other partner drugs, namely monodesethylamodiaquine (MDAQ), lumefantrine (LMF), mefloquine (MQ), artesunate (AS) and dihydroartemisinin (DHA) against 181 Plasmodium falciparum isolates from African countries, India and Thailand, and iii) in vitro cross-resistance with other quinoline drugs, chloroquine (CQ) or quinine (QN). Methods The susceptibility of the 181 P. falciparum isolates to the nine anti-malarial drugs was assessed using the standard 42-hours 3 H-hypoxanthine uptake inhibition method. Results The IC 50 values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM) and from 11.8 to 217.3 nM for PPQ (geometric mean = 66.8 nM). A significant positive correlation was shown between responses to PPQ and PND responses ( rho = 0.46) and between PPQ and MDAQ ( rho = 0.30). No significant correlation was shown between PPQ IC 50 and responses to other anti-malarial drugs. A significant positive correlation was shown between responses to PND and MDAQ ( rho = 0.37), PND and LMF ( rho = 0.28), PND and QN ( rho = 0.24), PND and AS ( rho = 0.19), PND and DHA ( rho = 0.18) and PND and CQ ( rho = 0.16). All these coefficients of correlation are too low to suggest cross-resistance between PPQ or PND and the other drugs. Conclusions In this study, the excellent anti-malarial activity of PPQ and PND was confirmed. The absence of cross-resistance with quinolines and artemisinin derivatives is consistent with the efficacy of the combinations of PPQ and DHA or PND and AS in areas where parasites are resistant to conventional anti-malarial drugs. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Rho ENVELOPE(-63.000,-63.000,-64.300,-64.300) Malaria Journal 11 1 45
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Malaria
Plasmodium falciparum
Anti-malarial
In vitro
Resistance
Pyronaridine
Piperaquine
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
spellingShingle Malaria
Plasmodium falciparum
Anti-malarial
In vitro
Resistance
Pyronaridine
Piperaquine
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Pascual Aurélie
Parola Philippe
Benoit-Vical Françoise
Simon Fabrice
Malvy Denis
Picot Stéphane
Delaunay Pascal
Basset Didier
Maubon Danièle
Faugère Bernard
Ménard Guillaume
Bourgeois Nathalie
Oeuvray Claude
Didillon Eric
Rogier Christophe
Pradines Bruno
Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
topic_facet Malaria
Plasmodium falciparum
Anti-malarial
In vitro
Resistance
Pyronaridine
Piperaquine
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
description Abstract Background The aim of the present work was to assess i) ex vivo activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities compared to other partner drugs, namely monodesethylamodiaquine (MDAQ), lumefantrine (LMF), mefloquine (MQ), artesunate (AS) and dihydroartemisinin (DHA) against 181 Plasmodium falciparum isolates from African countries, India and Thailand, and iii) in vitro cross-resistance with other quinoline drugs, chloroquine (CQ) or quinine (QN). Methods The susceptibility of the 181 P. falciparum isolates to the nine anti-malarial drugs was assessed using the standard 42-hours 3 H-hypoxanthine uptake inhibition method. Results The IC 50 values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM) and from 11.8 to 217.3 nM for PPQ (geometric mean = 66.8 nM). A significant positive correlation was shown between responses to PPQ and PND responses ( rho = 0.46) and between PPQ and MDAQ ( rho = 0.30). No significant correlation was shown between PPQ IC 50 and responses to other anti-malarial drugs. A significant positive correlation was shown between responses to PND and MDAQ ( rho = 0.37), PND and LMF ( rho = 0.28), PND and QN ( rho = 0.24), PND and AS ( rho = 0.19), PND and DHA ( rho = 0.18) and PND and CQ ( rho = 0.16). All these coefficients of correlation are too low to suggest cross-resistance between PPQ or PND and the other drugs. Conclusions In this study, the excellent anti-malarial activity of PPQ and PND was confirmed. The absence of cross-resistance with quinolines and artemisinin derivatives is consistent with the efficacy of the combinations of PPQ and DHA or PND and AS in areas where parasites are resistant to conventional anti-malarial drugs.
format Article in Journal/Newspaper
author Pascual Aurélie
Parola Philippe
Benoit-Vical Françoise
Simon Fabrice
Malvy Denis
Picot Stéphane
Delaunay Pascal
Basset Didier
Maubon Danièle
Faugère Bernard
Ménard Guillaume
Bourgeois Nathalie
Oeuvray Claude
Didillon Eric
Rogier Christophe
Pradines Bruno
author_facet Pascual Aurélie
Parola Philippe
Benoit-Vical Françoise
Simon Fabrice
Malvy Denis
Picot Stéphane
Delaunay Pascal
Basset Didier
Maubon Danièle
Faugère Bernard
Ménard Guillaume
Bourgeois Nathalie
Oeuvray Claude
Didillon Eric
Rogier Christophe
Pradines Bruno
author_sort Pascual Aurélie
title Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
title_short Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
title_full Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
title_fullStr Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
title_full_unstemmed Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
title_sort ex vivo activity of the act new components pyronaridine and piperaquine in comparison with conventional act drugs against isolates of plasmodium falciparum
publisher BMC
publishDate 2012
url https://doi.org/10.1186/1475-2875-11-45
https://doaj.org/article/9ec13234059144b18c4e63182e29403b
long_lat ENVELOPE(-63.000,-63.000,-64.300,-64.300)
geographic Arctic
Rho
geographic_facet Arctic
Rho
genre Arctic
genre_facet Arctic
op_source Malaria Journal, Vol 11, Iss 1, p 45 (2012)
op_relation http://www.malariajournal.com/content/11/1/45
https://doaj.org/toc/1475-2875
doi:10.1186/1475-2875-11-45
1475-2875
https://doaj.org/article/9ec13234059144b18c4e63182e29403b
op_doi https://doi.org/10.1186/1475-2875-11-45
container_title Malaria Journal
container_volume 11
container_issue 1
container_start_page 45
_version_ 1766346199062806528